Press Releases

11.07.2017

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration

Daiichi Sankyo, Max Planck Innovation GmbH and the Lead Discovery Center GmbH have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Center. continue

 

11.07.2017

FluxPharm licenses process for the cost-effective production of active pharmaceutical ingredients

The company FluxPharm has acquired a licence for a chemical process developed at the Max Planck Institute of Colloids and Interfaces in Potsdam. Using flow chemistry technology, the researchers at the Institute can now produce a variety of standard ingredients with much greater efficiency and more cost-effectively than with conventional methods. FluxPharm now intends to develop the technology and make it commercially available. The development of this process will boost the future production ... continue

 

22.05.2017

terraplasma medical successfully completes financing

The Munich-based medical technology company terraplasma medical GmbH successfully completed the first round of major financing (seed). The raised money, a seven-figure Euro amount, will be used to develop plasma care and establish the market approval. This mobile, battery-powered medical device for in- and outpatient treatment of chronic and acute wounds using cold plasma, which destroys fungi and even multi-resistant bacteria, is based on research of the Max Planck Institute for ... continue

 

11.05.2017

Cardior Pharmaceuticals raises €15 million

Cardior Pharmaceuticals today announced the completion of a €15 million series A financing round. Cardior is pioneering its proprietary RNA technology to revolutionize predicting and treating heart failure. The main technology is based on research from the Medical School Hannover (MHH) in cooperation with the Max Planck Institute for biophysical chemistry in Göttingen, amongst others. continue

 

05.05.2017

Teaching Robots to see what they do

The technology transfer organisation of the Max Planck Society has come to an agreement with the US start-up company Lula Robotics to use a technology for “continuous motion optimization and control”. Based on the technique from the Max Planck Institute for Intelligent Systems in Tübingen Lula Robotics is developing robots, which can act independently in complex environments. The goal is to create the bedrock for artificial aides supporting people in everyday life in the future. continue

 

25.04.2017

Life science technologies from the Max Planck Society at BioVaria

On 22 and 23 May, Max Planck Innovation will present two promising inventions at the BioVaria technology fair in Munich, one of which is a new therapy based on adult stem cells that makes continuous skin regeneration and the sustainable growth of new hair possible. An innovative diagnostic approach allows early non-invasive detection of lung cancer by means of a simple breath test. The technology transfer organization of the Max Planck Society is looking for industrial partners at the fair to ... continue

 

10.04.2017

PreOmics granted licence for proteomics technique

The start-up company PreOmics licenses several technologies of the Max Planck Institute of Biochemistry in Martinsried for the preparation of samples for proteomic research through Max Planck Innovation. In particular, an innovative sample preparation kit facilitates the use of mass spectrometry for research into proteins. In the future this could open up new opportunities in pharmaceutical development and diagnostics. continue

 

21.11.2016

FLASH technology - Jens Frahm inducted into the Hall of Fame of German Research

The physicist Jens Frahm, head of Biomedizinische NMR Forschungs GmbH at the Max Planck Institute for Biophysical Chemistry in Göttingen, has been inducted into the Hall of Fame of German Research. With this induction, ‘manager magazin’ is honouring the researcher for his pioneering further developments of magnetic resonance imaging (MRI). The FLASH technology he invented has made MRI today’s most important imaging method in clinical diagnostics and one which is used around the globe. An ... continue

 

14.11.2016

Vaxxilon named "Science Start-Up of the Year 2016"

Under the motto "Building bridges, transcending borders", 23 start-up companies presented their research projects at the Falling Walls Venture science competition on 8 November in Berlin. The company nominated by Max Planck Innovation, Vaxxilon, emerged as the winner and was proclaimed the "Science Start-Up of the Year 2016" for its development of a carbohydrate-based agent. The new agent should make vaccinations against bacterial infections cheaper in the future and thereby also improve ... continue

 

11.10.2016

License agreement: Photoswitch Biosciences develops drug discovery technology using optogenetics

Light-sensitive proteins discovered by Max Planck scientists are changing the way scientists study how new drug candidates affect critical properties of heart and nerve cells. Researchers can incorporate light-sensitive channelrhodopsin proteins into model cells grown in miniature test tube arrays. Using an instrument developed by Photoswitch Biosciences Incorporated, these light-sensitive ion channels can then be used to control the function of other ion channels of interest. Monitoring tiny ... continue

 

24.06.2016

Abberior Instruments Licenses Next Generation STED Technology

STED microscopy is a Nobel Prize awarded technology that allows to create highly resolved fluorescence images far below the diffraction limit. Earlier this year, researchers at the Max Planck Institute for Biophysical Chemistry in Göttingen have proposed and demonstrated their new Protected STED concept which enhances the image contrast and reduces photobleaching in STED microscopy by up to an order of magnitude. It is expected that their invention will particularly boost life-cell ... continue

 

11.05.2016

Novel approach for the treatment of schizophrenia

The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH and Boehringer Ingelheim International GmbH have signed an agreement providing Boehringer Ingelheim with the option to receive the exclusive rights to a new lead compound for the treatment of schizophrenia to be discovered and developed at the LDC. continue

 

01.12.2015

Max Planck Innovation joins TechnologieAllianz

Max Planck Innovation together with six other new members reinforces the nationwide Verband für Wissens- und Technologietransfer (Federation for the Transfer of Knowledge and Technology) from German universities and research facilities. The country's largest network for the exploitation of research results from the German scientific community offers industry access to Germany´s largest pool of patented high technology. continue

 

11.09.2015

Venneos raises seed round of 1 million euros

Venneos GmbH is based in Stuttgart and develops a novel imaging system for the analysis of biological cells. A consortium of business angels and family offices, along with the High-Tech Gründerfonds and Max Planck Society invest in the company to develop a market-ready product and prepare the market entry of the first product generation. continue

 

29.06.2015

The vaccines company

The Max Planck Society and Actelion found the start-up Vaxxilon to bring carbohydrate-based vaccines to market continue

 

03.06.2015

Licence Agreement on Novel Anti-cancer Compound

The Lead Discovery Center GmbH (LDC), a renowned translational drug discovery organization established by Max Planck Innovation, and Qurient Co., Ltd have signed a licence deal providing Qurient with exclusive worldwide rights to a series of highly-selective CDK7 inhibitors discovered at the LDC for the treatment of cancer, inflammation and viral infections. The partners will closely collaborate to advance the approach from the validated lead stage into clinical development. Upon successful ... continue

 

04.03.2015

IT incubator to commercialize research results of computer science in Saarbrücken

The ideas and inventions arising from research projects of the joint venture between Max Planck Society and Saarland University’s computer science department will in future to be further developed on campus and then marketed for application. Scientists can either set up their own companies or develop the technology to the stage where established businesses can purchase these licenses. In support of these scientists, Max Planck Society and Saarland University co-founded the IT Inkubator GmbH ... continue

 

08.10.2014

Nobel Prize in Chemistry 2014 for Max Planck researcher Stefan Hell

Stefan W. Hell, Director at the Max Planck Institute for Biophysical Chemistry in Göttingen has been awarded this year’s Nobel Prize in Chemistry. He shares the prize with Eric Betzig and William E. Moerner continue

 

22.05.2014

Profitable exit: KonTEM trade sale to FEI Company (NASDAQ: FEIC)

KonTEM GmbH, an HTGF-financed spin-off of the Max Planck Society and the research centre caesar, was taken over by FEI Company on a share deal basis. Thus the phase contrast technology developed by KonTEM is absorbed in the portfolio of a globally operating market leader in the field of high-performance microscopy workflow solutions. continue

 

16.04.2014

LDC Forms Early Drug Discovery Alliance with Daiichi Sankyo

Utilizing shared compound libraries for novel LDC targets

The Lead Discovery Center GmbH (LDC), a renowned translational research organization, and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), Japan, have teamed up to discover new medicines for the treatment of disease with high unmet medical needs. The partners will focus on targeted disease areas and novel mechanisms of strategic interest to Daiichi Sankyo, including oncology, cardiovascular and metabolic diseases. continue

 

05.03.2014

New 3D-image modelling technology enables anyone to have a 3D digital doppelgänger

Body Labs, Brown University, and the Max Planck Society Announce License Agreement continue

 

24.02.2014

LMU / MPG spin-off fights neurodegenerative diseases

MODAG GmbH secures financing for developing a new active substance against protein deposits responsible for Parkinson’s, Alzheimer’s and Creutzfeldt-Jakob continue

 

12.12.2013

Suicidality test being brought to market

U.S. company Sundance Diagnostics has licensed genetic markers that predict suicide risk when antidepressant drugs are prescribed

The new test, based on research carried out at the Max Planck Institute of Psychiatry, should help doctors to decrease the risk of suicidality in patients treated with antidepressants who show certain gene markers. Sundance plans to launch the test immediately as a laboratory developed test. In addition, clinical studies in support of a U.S. Food and Drug ... continue

 

05.12.2013

Anti-Cancer Program Originating from LDC Reaches Clinical Trials

First LDC-lead structure successfully progressed by Bayer Pharma AG into clinical study phase

The Lead Discovery Center GmbH (LDC) announces today that an innovative kinase inhibitor program licensed to Bayer Pharma AG, Germany (Bayer) in 2011, has been progressed to clinical trials. By 2012, Bayer had successfully advanced a lead compound from the program to the preclinical development stage. This fall, Bayer enrolled the first participant into a Phase I study to determine the ... continue

 

31.10.2013

Lead Discovery Center GmbH Announces Five-year Strategic Partnership with Merck Serono

Lead Discovery Center GmbH (LDC) a renowned translational research organization, today announced a five-year strategic partnership with Merck Serono, Darmstadt, Germany, the biopharmaceutical division of Merck. This collaboration integrates the expertise and resources of both organizations to expedite the discovery of promising lead structures and to optimize the development of therapeutic candidates in areas of high unmet medical need. continue

 

31.07.2013

Dolby Licenses Max Planck Imaging Technology

Dolby Laboratories, a world leader in audio and imaging technologies, has licensed an innovative imaging patent portfolio from the Max Planck Institute for Informatics – The technology relates to High Dynamic Range (HDR) imaging and increases the ability of images to show real world light intensities and color levels, while also reducing storage requirements. The technology provides an innovative design which makes it possible to achieve high picture quality from HDR-capable displays, while ... continue

 

23.07.2013

Serum Institute of India acquires rights to German TB vaccine – Researchers continue to refine classic TB vaccine

Hopes are high for a new and improved tuberculosis vaccine: Serum Institute of India is planning on taking a promising vaccine - originally developed in Germany - and introducing it into the clinical setting. Studies have shown that the new vaccine is more effective and better tolerated than currently available options. By signing a contract with the Hannover-based Vakzine Projekt Management GmbH (VPM), Serum, one of the World’s leading vaccine manufacturers, has effectively secured the ... continue

 

18.06.2013

Licencing agreement for high-resolution images in medical research

STED microscopy creates high-resolution images far below the diffraction limit of visible light. However, the technique’s engineering aspects remain comparatively complex, which impedes its dissemination and use. A technology called EASYDOnut, developed by the Max Planck Institute for Biophysical Chemistry and the German Cancer Research Center, simplifies the optical system considerably and has now been licenced by spin-off Abberior GmbH. EASYDOnut precisely guides the laser beams of the STED ... continue

 

12.03.2013

MPI of Biochemistry, LDC and Qurient Close License Deal on a New Compound against Metastatic and Drug-resistant Cancers

The Max Planck Institute of Biochemistry (MPIB), the Lead Discovery Center GmbH (LDC) and Qurient Co., Ltd have entered into a license agreement providing Qurient with world-wide, exclusive rights to a new kinase inhibitor for the treatment of metastatic cancer. continue

 

25.01.2013

LDC forms Drug Discovery alliance with AstraZeneca

The Lead Discovery Center GmbH (LDC) and AstraZeneca have joined forces to discover new medicines for the treatment of human diseases with high unmet medical need. Through a two-year collaboration, AstraZeneca will add 250,000 high-quality compounds to LDC’s internal screening collection to pursue projects in the areas of oncology, neuroscience, respiratory and inflammation, cardiovascular, gastrointestinal and infection research. continue

 

21.01.2013

Alliance of Translational Research Centres Established to Accelerate Global Drug Development

Six of the world’s top translational health research centres today announced that they have come together to form a new Global Alliance of Leading Drug Discovery and Development Centres. continue

 

08.01.2013

MPG Spin-off DRDx Concludes First Round of Financing with Support from QIAGEN and High-Tech Gründerfonds

The Hennigsdorf firm Drug Response Dx GmbH (DRDx GmbH) successfully concluded its first round of financing with High-Tech Gründerfonds and QIAGEN. The investment will serve to develop a biomarker test kit for rheumatoid arthritis treatment guidance with so-called TNF-alpha inhibitors. The test is secured by a unique patent platform exclusively in-licensed by the Max Planck Society (MPG). continue

 

26.11.2012

Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis

Joint Press Release of the German Center for Neurodegenerative Diseases and the Max Planck Research Unit for Enzymology of Protein Folding continue

 

20.09.2012

Anti-Cancer Project Originating from LDC Reaches Next Milestone

Successful Transfer into Pre-Clinical Drug Development at Bayer Pharma AG continue

 

18.07.2012

TandemLaunch licenses new 3D technology

Max Planck Innovation, the technology transfer organization of the Max Planck Society together with the Patent Marketing Agency of Saarland Universities have licensed a new method for processing digital stereo image content to TandemLaunch Technologies, a Canada based company, which develops multimedia inventions into consumer technologies. The new “Backward-compatible Stereo 3D” technology makes it possible to watch movies in 3D, when wearing glasses, and 2D without glasses at the same ... continue

 

26.06.2012

CARE will come

Stem cell researcher Schöler welcomes the provision in new NRW coalition agreement for the development of the Center for Advanced Regenerative Engineering (CARE) continue

 

21.06.2012

Incubation: Gentle stimuli for pain relief

Life Science Inkubator promotes new research team --- Scientists from the Life Science Inkubator (LSI) in Bonn, which was established by the technology transfer organisation Max Planck Innovation with the aim of facilitating spin-offs in the field of the life sciences, want to explore new directions in the area of pain therapy. The aim is to suppress pain using weak electric and mechanical stimuli. The stimulation will be generated using special bandages with integrated high-tech chips. ... continue

 

17.04.2012

High-Tech Gründerfonds invests in KonTEM GmbH

Joint press release of High-Tech Gründerfonds, Max-Planck-Innovation GmbH, Center of advanced european studies and research (caesar) and KonTEM GmbH --- KonTEM GmbH, a spin-off company of the Max-Planck-Gesellschaft (MPG) and the Center of advanced european studies and research (caesar), has developed an innovative phase contrast system for transmission electron microscopes (TEM). The system combines enhanced image contrast with high object resolution and thus opens up new possibilities ... continue

 

22.03.2012

Glowing colours to highlight the minutest details

Max Planck Innovation and Abberior sign licensing agreement for the development of fluorescent dyes for use in high-resolution microscopy continue

 

21.03.2012

Researchers at the LSI in Bonn overcome the blood-brain barrier with “GPS pill”

New prospects for the treatment of brain diseases continue

 

05.12.2011

Max Planck Society is hosting "Green Talent" winners

Young scientists from all over the world who are seeking solutions for the advancing climate change and who are developing sustainable strategies for the preservation of our natural environment are invited to Max Planck Society and its technology transfer organization Max Planck Innovation today. The winners of the prestigious "Green Talents" competition of the German Federal Ministry of Education and Research (BMBF) have the opportunity to gather specific information about research ... continue

 

16.11.2011

Max Planck Innovation gets caesar spin-off KonTEM under way

Spin-off company develops phase contrast for electron microscopy continue

 

11.11.2011

License Agreement Between Leica Microsystems, the Max Planck Society and the German Cancer Research Center

Developing the Next STED Generation continue

 

15.09.2011

Max Planck Society partners with Sanofi to Develop Innovative Solutions for Restoring Vision

New collaboration reinforces Sanofi’s translational discovery platform for retinal diseases continue

 

12.05.2011

Research prize for invention that treats chronic wounds

A research team from the Max Planck Institute for Extraterrestrial Physics and the Klinikum Schwabing hospital was awarded the Fondation URGO’s 2010 research prize on 10 May 2011 for its plasma technology. The invention enables the destruction of bacteria in chronically infected wounds and promotes wound healing in this way. continue

 

11.05.2011

Software for the discovery of new crystal structures

A new software called QED (Quantitative Electron Diffraction), which has been licensed by Max Planck Innovation, has now been released by HREM Research Inc., a Japan based company, which is developing products and services in the field of High-Resolution Electron Microscopy. QED allows transmission electron microscopes to acquire novel kinds of data, opening up new possibilities in electron crystallography. continue

 

18.04.2011

Lead Discovery Center and Bayer enter into license agreement covering a novel pharmaceutical lead structure

Out-licensing of the first pharmaceutical lead structure generated at the Lead Discovery Center for further development into a cancer therapy. continue

 

10.02.2011

Evotec acquires MPS-spin-off Kinaxo

Evotec AG, a leading company in the discovery and development of novel small molecule drugs, acquired all shares of Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs. With the acquisition of the MPS-spin-off Kinaxo and before Develogen AG several excellent technologies from different Max-Plancks Institutes are now powerfully brought together and continued under the roof of the Evotec AG, which had also arisen from a ... continue

 

20.01.2011

Lead Discovery Center and Merck KGaA Enter Collaboration for the Discovery of Anti-Cancer Compounds – Research collaboration may realize the potential of kinase inhibitors as a means for cancer treatments in the future

The Lead Discovery Center GmbH (LDC), a small molecule drug discovery spin-off of Max Planck Innovation GmbH, announced today that it has signed a cooperation agreement with Merck KGaA for the discovery of kinase inhibitors as potential cancer treatments. continue

 

02.12.2010

Alnylam's Tuschl II Patent Fully Upheld in European Opposition Proceedings - Decision of European Patent Office Validates Significance of Exclusively Held Tuschl II Patent for RNAi Therapeutics -

continue

 

27.10.2010

Max Planck Innovation licenses analysis-technology for metabolites

Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society awards an exclusive license for the analysis software TagFinder to Metabolomic Discoveries GmbH, a service provider in biochemical research. The new technology is part of an innovative procedure which makes it possible to measure and interpret virtually all chemical substances within a biological sample. This way processes in industrial biotechnology and food quality can be improved. continue

 

26.07.2010

Max Planck Innovation awards license for actin marker LifeAct

Max Planck Innovation and ibidi sign license agreement for cytoskeleton research Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, awards an exclusive license for LifeAct to ibidi GmbH, a provider of cell analysis products, located in Martinsried near Munich. The novel peptide allows for actin, an important protein, to be made visible in living cells without disturbing the actin dependent processes. Therefore, cells as well as the development of ... continue

 

10.03.2010

Max Planck Innovation licenses innovative sampling system to bbi-biotech

Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, is concluding two exclusive licensing agreements for a liquid sampling system with bbi-biotech GmbH, an innovative biotechnology company. The technology, developed at the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg, provides a sterile and economical way of taking samples for bioprocess analysis. continue

 

12.11.2009

Max Planck Innovation awards license to Solexel for an innovative method to develop thin-film solar cells

Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, Germany’s leading basic research organization, has signed a co-exclusive license agreement for its Porous-Silicon-Process (PSI process) technology with Solexel, Inc., a company focusing on the development and commercialisation of high-efficiency thin-film photovoltaic arrays and solar modules. continue

 

13.10.2009

Max Planck Innovation grants rights for developing new nanoscopic method to Leica Microsystems

Max Planck Innovation, the technology transfer organization of the Max Planck Society, grants Leica Microsystems, Wetzlar, an exclusive license for implementing the latest generation of optical microscopes with a resolution far below the diffraction limit (nanoscopes). This innovative optical nanoscopy, named GSDIM (ground state depletion microscopy followed by individual molecule return), achieves image resolutions in the nanometer range – even in conventional wide field microscopes. GSDIM ... continue

 

18.08.2009

Max Planck Innovation announces an exclusive licensing agreement with PerkinElmer for its Silicon Photomultiplier (SiPM) Technology

Max Planck Innovation, the technology transfer organization of the Max Planck Society, has entered into an exclusive licensing agreement with PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, for its ultra-fast, low cross-talk solid state silicon photomultiplier (SiPM) technology. continue

 

14.05.2009

Max Planck Innovation and LSP to launch DDC Ventures, a new pharmaceutical Venture Capital Fund

Max Planck Innovation GmbH, the technology transfer arm of Germany’s Max Planck Society, has today announced that LSP, a leading European venture fund manager, has been appointed to manage a new EUR 100 million venture capital fund. The fund will make investments into pharmaceutical projects primarily originating from the life science institutes of the Max Planck Society, one of the world’s most renowned research organisations. continue

 

30.09.2008

Max Planck Innovation's Drug Discovery and Development Center Wins BioPharma Strategy Competition

Project will receive €20 million in funding from the BMBF - Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society (MPG), announces today that its concept for a novel Drug Discovery and Development Center (DDC) will receive €20 million in funding from the German Ministry of Education and Research (BMBF) through its initiative "BioPharma - The strategy competition for medicine of the future". The DDC was selected as one of three winners that were presented ... continue

 

21.07.2008

Dafra Pharma R&D has been awarded an exclusive licence from the Max Planck Society to develop a drug against leishmaniasis

Max Planck Innovation, the technology transfer agency of the Max Planck Society based in Munich, Germany and Dafra Pharma R&D, a Belgian research company belonging to Dafra Pharma International, signed a license agreement today for the development and commercialisation of a new drug against leishmaniasis. continue

 

17.06.2008

Lead Discovery Center Starts Operations

Supporting the development of novel medicines in Germany - Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, announces today the opening of its new subsidiary, the Lead Discovery Center GmbH (LDC). It will be based in Dortmund, Germany, and intends to employ a staff of 15-20 experienced drug discovery scientists, project managers, and technical assistants by the end of 2008. continue

 

12.06.2008

Max Planck Innovation Receives IPTEC Award for Excellence in Technology Transfer

Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, was honored for outstanding achievement in developing technology transfer and licensing in the public sector. The award was presented yesterday, June 11, during the third International Marketplace and Conference for Technology Transfer Professionals (IPTEC) in Frankfurt. continue

 

03.03.2008

Max Planck Innovation's Drug Discovery Center Selected for Final Round of the BioPharma Strategy Competition

Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, announces today that its concept for a novel Drug Discovery Center (DDC) has reached the final round of the "BioPharma - strategy competition for medicine of the future", a support program of the German Ministry of Education and Research (BMBF). continue

 

12.12.2007

Max Planck Innovation and AmVac Enter Partnership for the Development of Novel Vaccines

Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, has closed a license agreement with Swiss AmVac AG, a biopharmaceutical company focused on the development and commercialization of innovative vaccines. Under the terms of the agreement, AmVac obtains the exclusive right to further develop and commercialize a technology that enables the design and production of a new class of vaccines with improved safety and efficacy. In return, Max Planck Innovation receives ... continue

 

29.10.2007

Max Planck Innovation and FuMA-Tech sign exclusive licencing agreement for novel fuel cell technology

New membrane material solves crucial problem for methanol-based fuel cells continue

 

01.08.2007

Alnylam Receives Allowance from European Patent Office for Tuschl II Patent, Exclusively Licensed from Max Planck Society

Tuschl II Patent in Europe Covers Compositions, Methods, and Uses of Small Interfering RNAs in World's Second Largest Pharmaceutical Market / Tuschl II Patent also Granted in Australia continue

 

21.05.2007

Max Planck Innovation Concludes Licensing Agreement for Technology Providing Unlimited Resolution in Microscopy

Overcoming Abbe's law in light microscopy continue

 

15.02.2007

KeyNeurotek AG and Max Planck Society sign licence and cooperation agreement for drug development

continue

 

06.02.2007

Max Planck Innovation Concludes Diagnostic microRNA Licensing Agreement

Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, Germany's leading basic research organization, has signed a co-exclusive license agreement with Stratagene Corporation (NASDAQ:STGN), a developer, manufacturer and marketer of specialized life science research and diagnostic products. Under the terms of the agreement, Stratagene has been granted rights to patents covering more than 150 human microRNA sequences for use in diagnostic applications. continue

 

23.10.2006

From Garching Innovation to Max Planck Innovation

The technology transfer company of the Max Planck Society will operate under the new name Max Planck Innovation. continue

 

21.08.2006

Max Planck Research leads to EU approval for cancer medication

The European Union has now approved SUTENT®. The basic mechanism behind the medication was discovered in the 1990s by Max Planck scientists, led by Prof. Axel Ullrich. The resulting patents were licensed by Garching Innovation GmbH, the technology transfer organisation of the Max Planck Society. continue

 

News alert

Do you want to receive our newsletter and press releases?
Subscribe here

Media contact

Markus Berninger
Phone: (089) 290919-30